Kenvue, the consumer arm of healthcare giant Johnson & Johnson, has launched a global creative review.
The company says the review is part of its regular business process as it seeks new ways to make an impact with consumers.
J&J announced plans to spin off Kenvue as a consumer health company in 2022. It owns brands such as Aveeno, Benadryl, Motrin, Listerine, Neutrogena, Calpol and Johnson's Baby.
Kenvue shares began trading last August. It defines itself as the world’s largest pure-play consumer health company by revenue. Wolff Olins designed the brand identity for Kenvue.
Omnicom's DDB Worldwide lists J&J among its clients. DDB Paris handles J&J's above-the-line brand business, while Omnicom sister agency BBDO handles J&J's corporate brand work.
A Kenvue spokesperson said: “Agency reviews are a part of our regular business process. We’re always looking for ways to ensure we’re making an even greater impact on the lives of the consumers and customers we serve."
DDB has been approached for comment.
GSK also spun off its consumer health unit, Haleon, in 2022.
.jpg&h=334&w=500&q=100&v=20170226&c=1)
.jpg&h=334&w=500&q=100&v=20170226&c=1)
.jpg&h=334&w=500&q=100&v=20170226&c=1)
.png&h=334&w=500&q=100&v=20170226&c=1)
.jpg&h=268&w=401&q=100&v=20170226&c=1)
